TEM
Tempus AIFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Execution on enterprise partnerships, successful FDA clearances, and accelerated dataset monetization drive sustained revenue growth, improved operating leverage, and multiple expansion.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.5.
What can break
Clinical validation or regulatory setbacks
Momentum
12
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $44.12 · Bull $68.39 · Bear $28.24
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $77.50
Why
Momentum12 · Δ7d +5.7
Value41 · Δ7d +0.0
Sentiment46 · Δ7d -5.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
12
34% active weight
Current posture
7d trendImproving
Δ7d
+5.7
Δ21d
-2.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
46
33% active weight
Current posture
7d trendSoftening
Δ7d
-5.5
Δ21d
+1.3
Why this grade
Composite grade F. Momentum 11.8 / Value 41.1 / Sentiment 46.0
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$9.06B
Beta
-
Shares Out
177.91M
P/E (TTM) · Derived
-36.2
P/S (TTM)
10.41
P/FCF (TTM) · Derived
-35.01
Rev YoY
+84.7%
EPS YoY
+0.2%
Gross Margin
+61.7%
Op Margin
-23.0%
Net Debt
-$12.83M
Current Ratio
3.28
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology